Advertisement

Clinical Research in Cardiology

, Volume 107, Issue 6, pp 460–470 | Cite as

The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry

  • Thomas A. Zelniker
  • Dörte Huscher
  • Anton Vonk-Noordegraaf
  • Ralf Ewert
  • Tobias J. Lange
  • Hans Klose
  • Daniel Dumitrescu
  • Michael Halank
  • Matthis Held
  • Henning Gall
  • David Pittrow
  • Marius M. Hoeper
  • Lutz Frankenstein
Original Paper

Abstract

Background

In patients with pulmonary arterial hypertension, the 6-Minute Walk Test (6MWT) is recommended for risk stratification and follow-up by all guidelines. However, the prognostic value of the 6MWT has been discussed controversially. We sought to compare and validate all published 6MWT cut-off points.

Methods

From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)—registry we identified 2391 patients with pulmonary arterial hypertension who had at least one documented 6MWT measurement. A Medline search identified a total of 21 different threshold values for either single-point or change of 6MWT. All values were tested individually for prognostication of 1-year, 2-year and 3-year all-cause mortality.

Results

The highest positive likelihood ratio was a cut-off value < 165 ms, whereas the best negative likelihood ratio was found to be a threshold of 440 ms. Furthermore, improvement in 6MWT had considerably less predictive value on mortality and survival than deterioration. Moreover, absolute single-point values outperformed change values for both improvement and worsening.

Conclusion

Our data confirmed the prognostic relevance of the 6MWT and support the cut-off values stated in most recent guidelines. Furthermore, these results explain why changes in 6MWT did not correlate consistently with prognosis in previous studies.

Keywords

Pulmonary arterial hypertension PAH 6-Minute walk test Risk stratification Cut-off value 

Notes

Acknowledgements

The authors are indebted to the COMPERA investigators.

Funding

This work was supported by the German Centre of Lung Research (DZL) and the Deutsche Forschungsgemeinschaft (Professor Hoeper, HO 1599/2-1). COMPERA is funded by unrestricted grants from Actelion Pharmaceuticals, Bayer and GSK. These companies were not involved in data analysis or the writing of this manuscript.

Compliance with ethical standards

Conflict of interest

Dr. Zelniker has nothing to disclose. Dr. Huscher reports personal fees from Actelion Pharmaceuticals, Switzerland outside the submitted work. AVN reports speakers fees from actelion, and Bayer outside the submitted work. Dr. Ewert has nothing to disclose. Dr. Lange reports other from Compera-Registry, during the conduct of the study; grants, personal fees and non-financial support from Actelion, grants, personal fees and non-financial support from Bayer, grants and personal fees from GlaxoSmithKline, personal fees from Pfizer, personal fees from MSD, grants and personal fees from United Therapeutics, outside the submitted work. Dr. Klose reports grants and personal fees from Actelion, grants and personal fees from GSK, personal fees from Pfizer, grants and personal fees from Bayer, personal fees from MSD, personal fees from United Therapeutics, personal fees from OMT, outside the submitted work. Dr. Dumitrescu reports other from COMPERA-Registry, during the conduct of the study; grants, personal fees and non-financial support from Actelion Pharmaceuticals, personal fees from Bayer, personal fees from GlaxoSmithKline, personal fees from Novartis, personal fees from Servier, outside the submitted work. Dr. Halank reports personal fees and non-financial support from Actelion, personal fees and non-financial support from Bayer, personal fees and non-financial support from GlaxoSmithKline, personal fees from OMT, personal fees from MSD SHARP & DOHME, personal fees from Pfizer, outside the submitted work. Dr. Held reports grants from Actelion, honoraria for lectures from Actelion, Bayer Healthcare, Berlin Chemie, Boehringer Ingelheim, GSK, MSD, Novartis, Pfizer, honoraria for advisory board activities from Actelion, Bayer, Boehringer, GSK, MSD, outside the submitted work and partizipation in clinical trails of Actelion, Bayer, GSK, Pfizer, United Therapeutics. Dr. Gall has nothing to disclose. Dr. Pittrow reports personal fees from Actelion, personal fees from Bayer, personal fees from Pfizer, outside the submitted work. Dr. Hoeper reports personal fees from Actelion, personal fees from Bayer, personal fees from Gilead, personal fees from GSK, personal fees from MSD, personal fees from Pfizer, outside the submitted work. Dr. Frankenstein has nothing to disclose.

References

  1. 1.
    Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43(12 Suppl S):13S-24S.  https://doi.org/10.1016/j.jacc.2004.02.029 PubMedCrossRefGoogle Scholar
  2. 2.
    Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, Newman JH, Rabinovitch M, Schermuly R, Stenmark KR, Voelkel NF, Yuan JX, Humbert M (2009) Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 54(1 Suppl):S10-19.  https://doi.org/10.1016/j.jacc.2009.04.006 CrossRefGoogle Scholar
  3. 3.
    Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M (2015) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 46(4):903–975.  https://doi.org/10.1183/13993003.01032-2015 CrossRefPubMedGoogle Scholar
  4. 4.
    Ewert R, Richter MJ, Steringer-Mascherbauer R, Grunig E, Lange TJ, Opitz CF, Warnke C, Ghofrani HA (2017) Intravenous treprostinil infusion via a fully implantable pump for pulmonary arterial hypertension. Clin Res Cardiol 106(10):776–783.  https://doi.org/10.1007/s00392-017-1114-1 CrossRefPubMedGoogle Scholar
  5. 5.
    McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, Palazzini M, Park MH, Tapson VF, Sitbon O (2013) Treatment goals of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D73-81.  https://doi.org/10.1016/j.jacc.2013.10.034 PubMedCrossRefGoogle Scholar
  6. 6.
    Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G, Guidelines ESCCfP (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30(20):2493–2537.  https://doi.org/10.1093/eurheartj/ehp297 CrossRefPubMedGoogle Scholar
  7. 7.
    McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, American College of Cardiology Foundation Task Force on Expert Consensus D, American Heart A, American College of Chest P, American Thoracic Society I, Pulmonary Hypertension A (2009) ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53 (17):1573–1619.  https://doi.org/10.1016/j.jacc.2009.01.004 CrossRefPubMedGoogle Scholar
  8. 8.
    Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ, Pulmonary Arterial H, Response to Tadalafil Study G (2009) Tadalafil therapy for pulmonary arterial hypertension. Circulation 119(22):2894–2903.  https://doi.org/10.1161/CIRCULATIONAHA.108.839274 CrossRefPubMedGoogle Scholar
  9. 9.
    Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346(12):896–903.  https://doi.org/10.1056/NEJMoa012212 CrossRefPubMedGoogle Scholar
  10. 10.
    Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G, Sildenafil Use in Pulmonary Arterial Hypertension Study G (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (20):2148–2157.  https://doi.org/10.1056/NEJMoa050010 CrossRefPubMedGoogle Scholar
  11. 11.
    Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ (2005) Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 46(3):529–535.  https://doi.org/10.1016/j.jacc.2005.04.050 CrossRefPubMedGoogle Scholar
  12. 12.
    Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ, Group P-S (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369(4):330–340.  https://doi.org/10.1056/NEJMoa1209655 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Fritz JS, Blair C, Oudiz RJ, Dufton C, Olschewski H, Despain D, Gillies H, Kawut SM (2013) Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. Chest 143(2):315–323.  https://doi.org/10.1378/chest.12-0270 CrossRefPubMedGoogle Scholar
  14. 14.
    Gaine S, Simonneau G (2013) The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension. Eur Respir Rev 22(130):487–494.  https://doi.org/10.1183/09059180.00006213 CrossRefPubMedGoogle Scholar
  15. 15.
    McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galie N, Gibbs JS, Kim NH, Oudiz RJ, Peacock A, Provencher S, Sitbon O, Tapson VF, Seeger W (2009) End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 54(1 Suppl):S97-107.  https://doi.org/10.1016/j.jacc.2009.04.007 PubMedCrossRefGoogle Scholar
  16. 16.
    Savarese G, Paolillo S, Costanzo P, D’Amore C, Cecere M, Losco T, Musella F, Gargiulo P, Marciano C, Perrone-Filardi P (2012) Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 60(13):1192–1201.  https://doi.org/10.1016/j.jacc.2012.01.083 CrossRefPubMedGoogle Scholar
  17. 17.
    Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, Grunig E, Staehler G, Rosenkranz S, Halank M, Held M, Lange TJ, Behr J, Klose H, Claussen M, Ewert R, Opitz CF, Vizza CD, Scelsi L, Vonk-Noordegraaf A, Kaemmerer H, Gibbs JS, Coghlan G, Pepke-Zaba J, Schulz U, Gorenflo M, Pittrow D, Hoeper MM (2014) Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation 129(1):57–65.  https://doi.org/10.1161/CIRCULATIONAHA.113.004526 CrossRefPubMedGoogle Scholar
  18. 18.
    Hoeper MM, Huscher D, Pittrow D (2015) Incidence and prevalence of pulmonary arterial hypertension in Germany. Int J Cardiol 203:612–613.  https://doi.org/10.1016/j.ijcard.2015.11.001 CrossRefPubMedGoogle Scholar
  19. 19.
    Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB (2013) Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D42-50.  https://doi.org/10.1016/j.jacc.2013.10.032 PubMedCrossRefGoogle Scholar
  20. 20.
    Pittrow D, Ghofrani HA, Opitz CF, Huscher D, Hoeper MM (2009) [International, prospective register for the documentation of first-line and maintenance therapy in patients with pulmonary hypertension (CompERA-XL)]. Dtsch Med Wochenschr 134(Suppl 5):S173–S175.  https://doi.org/10.1055/s-0029-1225318 CrossRefPubMedGoogle Scholar
  21. 21.
    Laboratories ATSCoPSfCPF (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166(1):111–117.  https://doi.org/10.1164/ajrccm.166.1.at1102 CrossRefGoogle Scholar
  22. 22.
    Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, Frost A, Barst RJ, Badesch DB, Elliott CG, Liou TG, McGoon MD (2010) Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 122(2):164–172.  https://doi.org/10.1161/CIRCULATIONAHA.109.898122 CrossRefPubMedGoogle Scholar
  23. 23.
    Gilbert C, Brown MC, Cappelleri JC, Carlsson M, McKenna SP (2009) Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest 135(1):137–142.  https://doi.org/10.1378/chest.07-0275 CrossRefPubMedGoogle Scholar
  24. 24.
    Gabler NB, French B, Strom BL, Palevsky HI, Taichman DB, Kawut SM, Halpern SD (2012) Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 126(3):349–356.  https://doi.org/10.1161/CIRCULATIONAHA.112.105890 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Mathai SC, Puhan MA, Lam D, Wise RA (2012) The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 186(5):428–433.  https://doi.org/10.1164/rccm.201203-0480OC CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Frost AE, Badesch DB, Miller DP, Benza RL, Meltzer LA, McGoon MD (2013) Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis. Chest 144(5):1521–1529.  https://doi.org/10.1378/chest.12-3023 CrossRefPubMedGoogle Scholar
  27. 27.
    McGee S (2002) Simplifying likelihood ratios. J Gen Intern Med 17(8):646–649CrossRefPubMedGoogle Scholar
  28. 28.
    Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ, Ambrisentan in Pulmonary Arterial Hypertension RD-BP-CMESG (2008) Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117 (23):3010–3019.  https://doi.org/10.1161/CIRCULATIONAHA.107.742510 CrossRefPubMedGoogle Scholar
  29. 29.
    Barst RJ, Langleben D, Frost A, Horn EM, Oudiz R, Shapiro S, McLaughlin V, Hill N, Tapson VF, Robbins IM, Zwicke D, Duncan B, Dixon RA, Frumkin LR, Group S-S (2004) Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 169(4):441–447.  https://doi.org/10.1164/rccm.200307-957OC CrossRefPubMedGoogle Scholar
  30. 30.
    Farber HW, Miller DP, McGoon MD, Frost AE, Benton WW, Benza RL (2015) Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. J Heart Lung Transplant 34(3):362–368.  https://doi.org/10.1016/j.healun.2014.08.020 CrossRefPubMedGoogle Scholar
  31. 31.
    Benza RL, Miller DP, Foreman AJ, Frost AE, Badesch DB, Benton WW, McGoon MD (2015) Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. J Heart Lung Transplant 34(3):356–361.  https://doi.org/10.1016/j.healun.2014.09.016 CrossRefPubMedGoogle Scholar
  32. 32.
    Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, Bancel DF, Allanore Y, Muller-Ladner U, Distler O, Iannone F, Pellerito R, Pileckyte M, Miniati I, Ananieva L, Gurman AB, Damjanov N, Mueller A, Valentini G, Riemekasten G, Tikly M, Hummers L, Henriques MJ, Caramaschi P, Scheja A, Rozman B, Ton E, Kumanovics G, Coleiro B, Feierl E, Szucs G, Von Muhlen CA, Riccieri V, Novak S, Chizzolini C, Kotulska A, Denton C, Coelho PC, Kotter I, Simsek I, de la Pena Lefebvre PG, Hachulla E, Seibold JR, Rednic S, Stork J, Morovic-Vergles J, Walker UA (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 69(10):1809–1815.  https://doi.org/10.1136/ard.2009.114264 CrossRefPubMedGoogle Scholar
  33. 33.
    Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, Dromer C, Pison C, Reynaud-Gaubert M, Haloun A, Laurent M, Hachulla E, Cottin V, Degano B, Jais X, Montani D, Souza R, Simonneau G (2010) Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 122(2):156–163.  https://doi.org/10.1161/CIRCULATIONAHA.109.911818 CrossRefPubMedGoogle Scholar
  34. 34.
    Lee WT, Peacock AJ, Johnson MK (2010) The role of per cent predicted 6-min walk distance in pulmonary arterial hypertension. Eur Respir J 36(6):1294–1301.  https://doi.org/10.1183/09031936.00155009 CrossRefPubMedGoogle Scholar
  35. 35.
    Frankenstein L, Remppis A, Graham J, Schellberg D, Sigg C, Nelles M, Katus HA, Zugck C (2008) Gender and age related predictive value of walk test in heart failure: do anthropometrics matter in clinical practice? Int J Cardiol 127(3):331–336.  https://doi.org/10.1016/j.ijcard.2007.04.087 CrossRefPubMedGoogle Scholar
  36. 36.
    Frankenstein L, Zugck C, Nelles M, Schellberg D, Katus H, Remppis A (2008) Sex-specific predictive power of 6-minute walk test in chronic heart failure is not enhanced using percent achieved of published reference equations. J Heart Lung Transplant 27(4):427–434.  https://doi.org/10.1016/j.healun.2008.01.010 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Thomas A. Zelniker
    • 1
  • Dörte Huscher
    • 2
  • Anton Vonk-Noordegraaf
    • 3
  • Ralf Ewert
    • 4
  • Tobias J. Lange
    • 5
  • Hans Klose
    • 6
  • Daniel Dumitrescu
    • 7
  • Michael Halank
    • 8
  • Matthis Held
    • 9
  • Henning Gall
    • 10
  • David Pittrow
    • 11
  • Marius M. Hoeper
    • 12
    • 13
  • Lutz Frankenstein
    • 1
  1. 1.Department of Cardiology, Angiology, PneumologyUniversity of HeidelbergHeidelbergGermany
  2. 2.Epidemiology UnitGerman Rheumatism Research CentreBerlinGermany
  3. 3.Department of Pulmonary DiseasesVU University Medical CenterAmsterdamThe Netherlands
  4. 4.Department of Internal MedicineUniversity of GreifswaldGreifswaldGermany
  5. 5.Department of Internal Medicine II, Division of PneumologyUniversity Medical Center RegensburgRegensburgGermany
  6. 6.Department of Respiratory MedicineUniversity Medical Center Hamburg-Eppendorf, Center of OncologyHamburgGermany
  7. 7.Herzzentrum der Universität zu Köln, Klinik III für Innere MedizinCologneGermany
  8. 8.Department of Internal Medicine I, Carl Gustav Carus University HospitalTechnical University of DresdenDresdenGermany
  9. 9.Department of Internal Medicine, Respiratory Medicine and CardiologyMissioClinicWürzburgGermany
  10. 10.Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL)GiessenGermany
  11. 11.Institute for Clinical Pharmacology, Medical FacultyTechnical University DresdenDresdenGermany
  12. 12.Department of Respiratory MedicineHannover Medical SchoolHannoverGermany
  13. 13.German Centre of Lung Research (DZL/BREATHE)HannoverGermany

Personalised recommendations